Pharmacists in Anthony, TX Accepting Medicare
4 Pharmacists found. Showing 1 - 4
 Dr. Andre Gilberto Montes, R.PH. , PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1432 Antonio St, Anthony, TX 79821 Phone: 915-886-2413 |
Dr. John Milton Bodlien, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1432 Antonio St, Anthony, TX 79821 Phone: 915-886-2413 Fax: 915-886-2125 |
 Karla Adriana Cuaron, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1432 Antonio St, Anthony, TX 79821 Phone: 915-886-2413 |
Jonathan Ushio Ugege, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 816 Franklin St Ste A, Anthony, TX 79821 Phone: 915-886-7222 Fax: 915-886-7226 |
News Archive
Coronary CTA reveals different heart attack risk scenarios for men and women
Findings on coronary CT angiography (CTA), a noninvasive test to assess the coronary arteries for blockages, show different risk scenarios for men and women, according to a study presented today at the Radiological Society of North America.
Diasorin migrates to Orange Business Services' Business VPN solution
Diasorin S.p.A., an international player in the market of in vitro diagnostics based in Saluggia (Vercelli, Italy), has migrated to Business VPN, a fully-managed, secure, global IP infrastructure from Orange Business Services connecting 12 locations in Europe, the Americas and Asia.
Study investigates muscle weakness in mouse model of Down syndrome
It is well known that people with Down syndrome (DS) suffer from marked muscle weakness. Even the simple tasks of independent living, such as getting out of a chair or climbing a flight of stairs, can become major obstacles. This can reduce the quality of life for those with DS and lead to a loss of independence. Now, a new study sheds light on some of the suspected causes of muscle weakness.
Dexmedetomidine may be an effective treatment option for opioid-induced hyperalgesia
Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).
Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product
BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).
› Verified 8 days ago